The present invention relates to a beneficial treatment of tumours in patients suffering from NSCLC, and to a clinical marker useful as predictive variable of the responsiveness of tumours in patients suffering from NSCLC. The present invention further relates to a method for selecting patients likely to respond to a given therapy, wherein said method optionally comprises the use of a specific clinical marker. The present invention further relates to a method for delaying disease progression and/or prolonging patient survival of NSCLC patients, wherein said method comprises the use of a specific clinical marker.本發明係關於一種對罹患NSCLC患者之腫瘤之有利治療及一種可用作罹患NSCLC患者之腫瘤之反應性之預測變量之臨床標記。本發明另外係關於一種用於選擇可能對給定療法起反應之患者之方法，其中該方法視情況包括使用特定臨床標記。本發明另外係關於一種延遲疾病進展及/或延長NSCLC患者之患者存活期之方法，其中該方法包括使用特定臨床標記。
